ADAR1 Capital Management »

Aeglea Biotherapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $1.9M 50k 37.93
2023-12-31 $139k 6.4k 21.52

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Aeglea Biotherapeutics

Fairmount Funds Management
Perceptive Advisors
VR Adviser
BlackRock
BlackRock
Braidwell
Commodore Capital
Vanguard Group
Deep Track Capital
State Street Corporation
Paradigm Biocapital Advisors
Assenagon Asset Management
Goldman Sachs Group
Geode Capital Management
Pictet Asset Management Holding SA

View all funds holding Aeglea Biotherapeutics